Arca
Skip to content
Tools
Tools

Medicare Drug Spending

How much Medicare, the US health plan for people 65 and older, spent on each drug, and which costs grew fastest.

Medicare Part D and Part B spent $428.1B on drugs in 2025 before manufacturer rebates, up 22% from 2024. Mounjaro grew the most, from $6.34B to $14.1B.

  • Spending, 2025: $428.1B
  • Change from 2024: +22%
  • Janโ€“Jun 2026: $197.2B
  • Drugs with spending: 4,238

Spending by year, 2020โ€“2025

Gross Part D and Part B drug spending each year; Janโ€“Jun 2026 so far: $197.2B.

Negotiated drugs: spending Janโ€“Jun 2026 vs 2025

The first 10 drugs with Medicare-negotiated prices, in effect since Jan 1, 2026: Janโ€“Jun 2026 spending against the same share of 2025's total. Where cheaper generic or biosimilar copies also launched, part of the drop is theirs. Late claims can still raise recent quarters a little.

Biggest increases, 2024 to 2025

Dollar growth among drugs Medicare already paid for at the start. Part B skin substitutes are billed per square centimeter. Click a drug to find it below.

Largest, 2025

Gross spending by brand. Click a drug to find it below.

The 1,000 largest of the 4,238 drugs with 2025 spending

Part2020โ€“2025
EliquisApixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery.ApixabanPart D$24.0B2020: $9.94B 2021: $12.6B 2022: $15.2B 2023: $18.3B 2024: $20.8B 2025: $24.0B+142%+16%$5.38B4,806,652
OzempicSemaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes.SemaglutidePart D$16.2B2020: $1.46B 2021: $2.62B 2022: $4.63B 2023: $9.19B 2024: $13.0B 2025: $16.2B+1,010%+25%$8.31B2,044,696
JardianceEmpagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes.EmpagliflozinPart D$15.1B2020: $2.38B 2021: $3.74B 2022: $5.85B 2023: $8.84B 2024: $11.4B 2025: $15.1B+535%+32%$2.80B2,977,849
MounjaroTirzepatide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes.TirzepatidePart D$14.1B2020: โ€” 2021: โ€” 2022: $144M 2023: $2.36B 2024: $6.34B 2025: $14.1BNew 2022+122%$9.99B1,592,437
FarxigaDapagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes.Dapagliflozin PropanediolPart D$6.72B2020: $737M 2021: $1.42B 2022: $2.58B 2023: $4.34B 2024: $5.29B 2025: $6.72B+812%+27%$591M1,421,682
XareltoRivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery.RivaroxabanPart D$6.55B2020: $4.70B 2021: $5.23B 2022: $5.77B 2023: $6.31B 2024: $6.23B 2025: $6.55B+39%+5%$1.12B1,258,731
Trelegy ElliptaThis product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonaryโ€ฆFluticasone/Umeclidin/VilanterPart D$6.45B2020: $1.49B 2021: $2.39B 2022: $3.34B 2023: $4.46B 2024: $5.29B 2025: $6.45B+334%+22%$3.22B1,373,291
KeytrudaPembrolizumab is used to treat cancer.PembrolizumabPart B$6.36B2020: $3.50B 2021: $3.97B 2022: $4.94B 2023: $5.43B 2024: $5.99B 2025: $6.36B+82%+6%$3.11B77,676
XtandiEnzalutamide is used to treat prostate cancer.EnzalutamidePart D$5.13B2020: $1.97B 2021: $2.41B 2022: $2.44B 2023: $2.60B 2024: $3.40B 2025: $5.13B+161%+51%$2.62B48,506
TrulicityDulaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes.DulaglutidePart D$4.83B2020: $3.28B 2021: $4.70B 2022: $6.23B 2023: $7.36B 2024: $5.45B 2025: $4.83B+47%โˆ’12%$2.10B582,306
Humira (CF) PenAdalimumab is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, ankylosing spondylitis).AdalimumabPart D$4.64B2020: $2.17B 2021: $2.91B 2022: $3.69B 2023: $4.42B 2024: $4.33B 2025: $4.64B+114%+7%$1.35B70,053
BiktarvyThis combination product is used by itself to help control HIV infection.Bictegrav/Emtricit/Tenofov AlaPart D$4.01B2020: $1.78B 2021: $2.20B 2022: $2.70B 2023: $3.15B 2024: $3.46B 2025: $4.01B+126%+16%$2.08B101,550
Dupixent PenThis medication is used to treat certain skin conditions (eczema, prurigo nodularis, bullous pemphigoid) and a certain esophagus problem (eosinophilic esophagitis).DupilumabPart D$3.97B2020: $13.4M 2021: $207M 2022: $523M 2023: $1.08B 2024: $1.80B 2025: $3.97B+29,539%+120%$2.74B133,286
EntrestoThis product is used to treat certain types of heart failure.Sacubitril/ValsartanPart D$3.93B2020: $1.20B 2021: $1.72B 2022: $2.49B 2023: $3.43B 2024: $4.02B 2025: $3.93B+226%โˆ’2%$52.6M826,526
LenalidomideLenalidomide is used to treat various types of cancers.LenalidomidePart D$3.93B2020: โ€” 2021: โ€” 2022: $448M 2023: $1.68B 2024: $2.64B 2025: $3.93BNew 2022+49%$1.64B45,335
VyndamaxThis medication is used to treat a certain type of heart failure (transthyretin-mediated amyloidosis).TafamidisPart D$3.92B2020: $253M 2021: $532M 2022: $845M 2023: $1.35B 2024: $2.83B 2025: $3.92B+1,446%+38%$2.47B19,958
StelaraUstekinumab is used to treat plaque psoriasis, a certain type of arthritis (psoriatic arthritis), or certain bowel conditions (Crohn's disease, ulcerative colitis).UstekinumabPart D$3.23B2020: $1.11B 2021: $1.57B 2022: $2.34B 2023: $2.99B 2024: $3.38B 2025: $3.23B+192%โˆ’4%$265M24,946
Skyrizi PenThis medication is used to treat plaque psoriasis and psoriatic arthritis.Risankizumab-RzaaPart D$3.20B2020: โ€” 2021: $81.8M 2022: $595M 2023: $1.19B 2024: $1.78B 2025: $3.20BNew 2021+80%$2.08B44,574
Darzalex FasproThis medication is used to treat a certain type of cancer (multiple myeloma).Daratumumab-Hyaluronidase-FihjPart B$3.18B2020: โ€” 2021: $1.05B 2022: $1.58B 2023: $2.08B 2024: $2.53B 2025: $3.18BNew 2021+26%$1.80B31,345
Enbrel SureclickThis medication is used alone or in combination with an immunosuppressant (such as methotrexate) to treat certain types of arthritis (such as rheumatoid, psoriaticโ€ฆEtanerceptPart D$3.11B2020: $1.37B 2021: $1.53B 2022: $1.78B 2023: $2.05B 2024: $2.34B 2025: $3.11B+127%+33%$505M47,431
OfevThis medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease).Nintedanib EsylatePart D$2.96B2020: $1.16B 2021: $1.50B 2022: $1.76B 2023: $1.84B 2024: $2.09B 2025: $2.96B+156%+42%$1.01B31,813
AMCHOPLAST, PER SQ CMPart B$2.95B2020: โ€” 2021: โ€” 2022: โ€” 2023: โ€” 2024: โ€” 2025: $2.95BNew 2025New$32.2M4,365
RevlimidLenalidomide is used to treat various types of cancers.LenalidomidePart D$2.67B2020: $5.36B 2021: $5.89B 2022: $5.94B 2023: $3.86B 2024: $4.18B 2025: $2.67Bโˆ’50%โˆ’36%$546M26,111
Repatha SureclickEvolocumab is used along with a proper diet to help lower "bad" cholesterol (LDL) in the blood.EvolocumabPart D$2.63B2020: $312M 2021: $518M 2022: $753M 2023: $1.09B 2024: $1.71B 2025: $2.63B+742%+54%$1.67B539,118
ProliaDenosumab is used to treat bone problems that may occur in people with multiple myeloma or in people with cancer that has spread to the bones.DenosumabPart B$2.62B2020: $1.63B 2021: $1.78B 2022: $2.00B 2023: $2.19B 2024: $2.43B 2025: $2.62B+61%+8%$1.04B726,416
IbrancePalbociclib is used to treat a certain type of breast cancer.PalbociclibPart D$2.62B2020: $2.11B 2021: $1.89B 2022: $1.95B 2023: $2.02B 2024: $2.04B 2025: $2.62B+24%+29%$1.41B20,017
BrukinsaThis medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia, smallโ€ฆZanubrutinibPart D$2.56B2020: $12.5M 2021: $82.6M 2022: $303M 2023: $801M 2024: $1.72B 2025: $2.56B+20,372%+49%$1.63B23,842
CalquenceThis medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL).AcalabrutinibPart D$2.51B2020: $350M 2021: $775M 2022: $1.19B 2023: $1.35B 2024: $1.70B 2025: $2.51B+618%+48%$1.50B21,730
VabysmoFaricimab is used to treat certain serious eye conditions (such as wet age-related macular degeneration, macular edema).Faricimab-SvoaPart B$2.38B2020: โ€” 2021: โ€” 2022: $170M 2023: $1.30B 2024: $1.92B 2025: $2.38BNew 2022+24%$1.16B213,771
RinvoqUpadacitinib is used to treat certain types of arthritis (such as psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, polyarticular juvenile idiopathicโ€ฆUpadacitinibPart D$2.36B2020: $191M 2021: $412M 2022: $622M 2023: $976M 2024: $1.39B 2025: $2.36B+1,132%+70%$1.51B46,179
ImbruvicaThis medication is used to treat certain cancers (such as chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia).IbrutinibPart D$2.36B2020: $2.96B 2021: $3.15B 2022: $2.85B 2023: $2.37B 2024: $2.27B 2025: $2.36Bโˆ’21%+4%$620M14,772
LinzessSee also Warning section.LinaclotidePart D$2.35B2020: $1.14B 2021: $1.37B 2022: $1.58B 2023: $1.83B 2024: $1.98B 2025: $2.35B+105%+18%$599M692,704
JakafiThis medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera).Ruxolitinib PhosphatePart D$2.34B2020: $1.30B 2021: $1.49B 2022: $1.76B 2023: $1.94B 2024: $2.08B 2025: $2.34B+81%+12%$1.24B17,288
PomalystPomalidomide is used to treat certain types of cancers (such as multiple myeloma, Kaposi sarcoma).PomalidomidePart D$2.32B2020: $1.45B 2021: $1.60B 2022: $1.74B 2023: $1.71B 2024: $2.15B 2025: $2.32B+60%+8%$619M14,946
TagrissoThis medication is used to treat lung cancer.Osimertinib MesylatePart D$2.30B2020: $793M 2021: $913M 2022: $1.08B 2023: $1.23B 2024: $1.63B 2025: $2.30B+190%+41%$1.36B16,671
IngrezzaValbenazine is used to treat involuntary movements of the face, tongue, or other body parts (tardive dyskinesia).Valbenazine TosylatePart D$2.25B2020: $789M 2021: $919M 2022: $1.27B 2023: $1.71B 2024: $1.96B 2025: $2.25B+186%+15%$1.24B36,118
NubeqaDarolutamide is used to treat a certain type of prostate cancer.DarolutamidePart D$2.24B2020: $99.9M 2021: $224M 2022: $322M 2023: $576M 2024: $998M 2025: $2.24B+2,143%+125%$1.79B26,013
JanuviaSitagliptin is used with a proper diet and exercise program and possibly with other medications to control high blood sugar.Sitagliptin PhosphatePart D$2.15B2020: $3.87B 2021: $4.06B 2022: $4.10B 2023: $4.09B 2024: $3.81B 2025: $2.15Bโˆ’44%โˆ’44%$383M787,278
MyrbetriqThis medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity).MirabegronPart D$2.10B2020: $1.75B 2021: $1.99B 2022: $2.25B 2023: $2.51B 2024: $2.30B 2025: $2.10B+20%โˆ’9%$832M679,963
ErleadaApalutamide is used to treat men with prostate cancer.ApalutamidePart D$2.08B2020: $469M 2021: $735M 2022: $878M 2023: $1.06B 2024: $1.39B 2025: $2.08B+342%+50%$1.16B19,178
RybelsusSemaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes.SemaglutidePart D$2.03B2020: $73.4M 2021: $455M 2022: $975M 2023: $1.67B 2024: $1.89B 2025: $2.03B+2,663%+7%$1.05B280,448
OpdivoNivolumab is used to treat cancer.NivolumabPart B$2.00B2020: $1.59B 2021: $1.57B 2022: $1.85B 2023: $1.91B 2024: $1.93B 2025: $2.00B+26%+3%$905M26,984
Invega SustennaThis medication is used to treat certain mental/mood disorders (such as schizophrenia, schizoaffective disorder).Paliperidone PalmitatePart D$1.95B2020: $1.37B 2021: $1.50B 2022: $1.64B 2023: $1.82B 2024: $1.88B 2025: $1.95B+42%+4%$986M71,640
CreonThis medication contains digestive enzymes to help break down and digest fats, starch, and proteins in food.Lipase/Protease/AmylasePart D$1.86B2020: $960M 2021: $1.11B 2022: $1.31B 2023: $1.47B 2024: $1.49B 2025: $1.86B+94%+25%$892M184,879
TRI MEMBRANE WRAP, PER SQ CMPart B$1.83B2020: โ€” 2021: โ€” 2022: โ€” 2023: โ€” 2024: โ€” 2025: $1.83BNew 2025New$3.7M4,063
KisqaliRibociclib is used to treat breast cancer.Ribociclib SuccinatePart D$1.76B2020: $129M 2021: $119M 2022: $166M 2023: $371M 2024: $775M 2025: $1.76B+1,265%+127%$1.18B17,370
SIMPLIMAX, PER SQ CMPart B$1.54B2020: โ€” 2021: โ€” 2022: โ€” 2023: โ€” 2024: โ€” 2025: $1.54BNew 2025New$1.7M3,437
CabometyxThis medication is used to treat various types of cancer.Cabozantinib S-MalatePart D$1.54B2020: $381M 2021: $663M 2022: $919M 2023: $1.11B 2024: $1.22B 2025: $1.54B+305%+27%$826M11,335
EyleaAflibercept is used to treat certain serious eye conditions (such as macular edema/degeneration, diabetic retinopathy, retinopathy of prematurity).AfliberceptPart B$1.54B2020: $3.01B 2021: $3.42B 2022: $3.54B 2023: $3.15B 2024: $2.37B 2025: $1.54Bโˆ’49%โˆ’35%$478M222,243
VerzenioThis medication is used to treat certain types of breast cancer.AbemaciclibPart D$1.51B2020: $286M 2021: $325M 2022: $474M 2023: $757M 2024: $1.06B 2025: $1.51B+426%+43%$952M14,849

Gross Medicare spending by drug from CMS's yearly dashboards: Part D (pharmacy) and Part B (drugs given in clinics and hospital outpatient settings). Totals are before manufacturer rebates and discounts, so net spending is lower. Part D counts each brand's total across manufacturers. The newest full year and the running year come from CMS's quarterly files, earlier years from its yearly files. Part B rows are per billing code. โ€œUsed forโ€ lines are CMS's own descriptions where it gives one. CMS Medicare Part D and Part B Spending by Drug

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.